Marion Delcroix Selected Research

macitentan

1/2022	Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension.
1/2019	Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
1/2018	Macitentan in pulmonary hypertension due to left ventricular dysfunction.
1/2018	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.
1/2018	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.
1/2017	Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.
1/2017	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.
12/2015	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN.
1/2015	Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
8/2013	Macitentan and morbidity and mortality in pulmonary arterial hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marion Delcroix Research Topics

Disease

52	Pulmonary Hypertension 10/2022 - 08/2002
37	Pulmonary Arterial Hypertension 10/2022 - 05/2002
9	Familial Primary Pulmonary Hypertension 10/2022 - 05/2002
6	Pulmonary Embolism 04/2022 - 04/2008
5	Heart Failure 01/2022 - 01/2002
4	Hypoxia (Hypoxemia) 02/2017 - 09/2014
3	Hemorrhage 01/2021 - 03/2011
3	Chronic Obstructive Pulmonary Disease (COPD) 01/2021 - 01/2016
3	Dyspnea (Shortness of Breath) 10/2019 - 08/2002
3	Disease Progression 01/2017 - 06/2004
2	Vascular Diseases (Vascular Disease) 11/2021 - 10/2013
2	Hemoptysis 01/2021 - 12/2020
2	Diabetes Mellitus 12/2020 - 07/2013
2	Hypertension (High Blood Pressure) 12/2020 - 01/2002
2	Coronary Disease (Coronary Heart Disease) 12/2020 - 03/2016
2	Infections 11/2020 - 03/2011
2	Sarcoma (Soft Tissue Sarcoma) 01/2020 - 01/2017
2	Left Ventricular Dysfunction 01/2018 - 01/2018
2	Venous Thromboembolism 07/2013 - 11/2011
2	Eisenmenger Complex (Eisenmenger's Syndrome) 09/2011 - 06/2006
1	Lung Diseases (Lung Disease) 10/2022
1	Post-Acute COVID-19 Syndrome 01/2022
1	Hypotension (Low Blood Pressure) 01/2021
1	Obesity 12/2020
1	COVID-19 11/2020
1	Interstitial Lung Diseases (Interstitial Lung Disease) 10/2020
1	Leiomyomatosis 01/2020
1	Embolism (Embolus) 10/2019
1	Fatigue 10/2019
1	Connective Tissue Diseases (Connective Tissue Disease) 07/2019
1	Congenital Heart Defects (Congenital Heart Defect) 07/2019
1	Inflammation (Inflammations) 01/2019
1	Rare Diseases (Rare Disease) 01/2019
1	Secondary Hyperparathyroidism 01/2018
1	Weight Gain 01/2018
1	Heart Diseases (Heart Disease) 01/2018
1	Diarrhea 01/2018
1	Hypocalcemia 01/2018
1	Osteomalacia 01/2018
1	Osteoporosis 01/2018
1	Pulmonary Veno-Occlusive Disease (Veno Occlusive Disease, Pulmonary) 04/2016
1	Necrosis 01/2016

Drug/Important Bio-Agent (IBA)

10	macitentanIBA 01/2022 - 08/2013
9	Endothelin Receptor AntagonistsIBA 01/2020 - 06/2006
6	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/2020 - 05/2002
5	Pharmaceutical PreparationsIBA 07/2019 - 06/2004
3	Brain Natriuretic Peptide (Natrecor)FDA Link 10/2022 - 11/2018
3	riociguatIBA 01/2022 - 12/2020
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2020
3	Oxygen (Dioxygen)IBA 11/2021 - 10/2019
3	Soluble Guanylyl CyclaseIBA 01/2021 - 01/2020
3	Type II Bone Morphogenetic Protein Receptors (Bone Morphogenetic Protein Receptor Type II)IBA 10/2019 - 01/2016
3	Bosentan (Tracleer)FDA Link 01/2019 - 12/2008
2	Carbon MonoxideIBA 10/2022 - 12/2020
2	AnticoagulantsIBA 01/2022 - 01/2020
2	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 01/2017
2	DesminIBA 01/2020 - 03/2012
2	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 01/2019 - 11/2016
2	selexipagIBA 01/2018 - 10/2012
2	Sildenafil Citrate (Viagra)FDA Link 02/2017 - 04/2015
2	ProstaglandinsIBA 08/2013 - 06/2004
2	C-Reactive ProteinIBA 10/2012 - 04/2009
2	beraprostIBA 06/2004 - 05/2002
1	4- ((1,4,8,11- tetraazacyclotetradec- 1- yl)methyl)benzoic acidIBA 04/2022
1	Vitamin K FDA Link 01/2022
1	N(4)-oleylcytosine arabinosideIBA 01/2022
1	Guanosine Monophosphate (5' Guanylic Acid)IBA 12/2021
1	Vasodilator Agents (Vasodilators)IBA 12/2021
1	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 01/2021
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2020
1	Estrogen ReceptorsIBA 01/2020
1	Phosphodiesterase 5 InhibitorsIBA 01/2020
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2019
1	CytokinesIBA 10/2019
1	Interleukin-18 (Interleukin 18)IBA 10/2019
1	AntigensIBA 01/2019
1	N 30IBA 01/2019
1	Complement System Proteins (Complement)IBA 01/2019
1	DiureticsIBA 01/2018
1	Denosumab FDA Link 01/2018
1	hydralazine 4-anisaldehyde hydrazoneIBA 11/2016
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 04/2016
1	Interleukin-1 (Interleukin 1)IBA 01/2016
1	Proteins (Proteins, Gene)FDA Link 01/2016
1	Interleukin-6 (Interleukin 6)IBA 01/2016
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2016
1	calpastatinIBA 01/2016
1	InterleukinsIBA 01/2016
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2016

Therapy/Procedure

30	Therapeutics 10/2022 - 08/2002
20	Endarterectomy (Thromboendarterectomy) 03/2022 - 02/2005
3	Lung Transplantation 01/2018 - 02/2005
2	Heart-Lung Transplantation 07/2019 - 01/2002
2	Transplantation 09/2013 - 06/2006
2	Extracorporeal Membrane Oxygenation 03/2011 - 03/2005
1	Aftercare (After-Treatment) 01/2022
1	Precision Medicine 11/2021
1	Organ Transplantation 11/2020
1	Catheters 10/2019
1	Traction 02/2016